Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07191028 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Alzheimer's Disease THErapy With NEuroaid II

Study acronym: ATHENE II
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 2028 to Feb 2029v2 Show 6 more changesShow less
    • Start date: Dec 2025 to Aug 2026
    • Primary endpoint revised
    • Study completion date: Jun 2028 to May 2029
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: 6 to 4
    • Study description revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ATHENE II is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial designed to evaluate the efficacy and safety of MLC901 in subjects with mild to moderate Alzheimer's disease, as well as its effects on plasma biomarkers compared to placebo.
Trial Details
NCT Number NCT07191028
Lead Sponsor Moleac Pte Ltd.
Collaborators: National University Hospital, Singapore
Conditions
(from sponsor)		 Alzheimer's Disease Dementia
Related terms Alzheimer Disease
Enrollment 350 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov